ABOUT US About Celltrion Notice Media Center BUSINESS Business Areas R&D Production Distribution PRODUCTS Products Pipeline ESG Environmental Social Governance ESG Archive IR Financial Information Stock Summary Public Disclosures IR Archive CAREERS Our Values How to Apply Jobs KOR ENG Choose Other Countries Europe Asia Pacific North America Latin America close Denmark Finland (FI) Finland (SV) France Germany Hungary Ireland Italy Netherlands Norway (NO) Norway (SV) Poland Spain Sweden Switzerland Portugal Türkiye United Kingdom Korea (HQ) Korea (EN) Japan Australia New Zealand Vietnam Canada (EN) Canada (FR) USA Brazil Chile Colombia Mexico Peru
ALL Discovery Spotlight ESG People All Title Content delete search Discovery The Unsung Guardian of Patient Safety: The World of Biopharmaceutical Quality Control (QC) 2026.07.21 Discovery Chronic Inflammation That Attacks Your Body: A Guide to Rheumatoid Arthritis, from Symptoms to Treatment 2026.07.21 People Celltrion Acquires French Healthcare Company Gifrer to Strengthen Its Position in Europe 2026.07.03 ESG Bringing More Balance to Work and Life: Celltrion’s “Camo Class” 2026.05.29 Discovery Celltrion’s Biopharmaceutical and Antibody Therapeutics Development Expertise: Our Distinct Strengths 2026.05.29 Spotlight Meet Celltrion’s Europe Division, Leading Europe’s Direct-Sales Markets with 70% Market Share 2026.05.19 Discovery Inflammatory Bowel Disease (IBD): A Growing Global Health Challenge and the Evolving Treatment Paradigm Driven by Biopharmaceutical Innovation 2026.05.19 Discovery Formulation: Beyond Conventional Methods, Toward New Therapeutic Strategies 2025.09.29 Spotlight Celltrion's Open Innovation: Beyond Boundaries, Toward Innovation 2025.09.29 First 1 2 Last
![[IBD Guide] From Causes to Advanced Therapies Like Infliximab | Celltrion](https://cellhomeblob.blob.core.windows.net/files/board/stories/261908350515-aa767f8e-bb40-42bd-bd6b-72ab8ad1c30c.png)
